Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C

Journal of Virological Methods

Volumn 210, Issue , 2014, Pages 36-39

  Mutsvangwa, J ^a,b   Beck, I A ^c   Gwanzura, L ^a,b   Manhanzva, M T ^b   Stranix Chibanda, L ^b   Chipato, T ^b   Frenkel, L M ^c,d  

^a Biomedical Research and Training Institute (BRTI)   (Zimbabwe)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Genotyping; HIV; HIV drug resistance; Nevirapine; Oligonucleotide ligation assay; Point mutation

Indexed keywords

NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AMPLICON; ANTIVIRAL RESISTANCE; ARTICLE; ASSAY; CODON; COMPARATIVE STUDY; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; INFANT; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE LIGATION ASSAY; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; RNA SEQUENCE; SINGLE DRUG DOSE; VALIDATION STUDY; VIRUS MUTANT; VIRUS MUTATION; WILD TYPE; ZIMBABWE; GENETICS; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; NEWBORN; POINT MUTATION; SENSITIVITY AND SPECIFICITY; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; NEVIRAPINE; OLIGONUCLEOTIDE PROBES; POINT MUTATION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; ZIMBABWE;

EID: 84908517801     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.09.005     Document Type: Article

References (17)

1. Beck I.A., Crowell C., Kittoe R., Bredell H., Machaba M., Willamson C., Janssens W., Jallow S., van der Groen G., Shao Y., Jacob M., Samuel N.M., de Rivera I.L., Ngo-Giang-Huong N., Cassol S., Alemnji G., Frenkel L.M. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J. Acquir. Immune Defic. Syndr. 2008, 48:418-427. PMC2583356. 10.1097/QAI.0b013e31817ed7d7.
2. Beck I.A., Mahalanabis M., Pepper G., Wright A., Hamilton S., Langston E., Frenkel L.M. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J. Clin. Microbiol. 2002, 40:1413-1419. PMID 11923366. PMC140364.
3. Bennett D.E., Bertagnolio S., Sutherland D., Gilks C.F. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 2008, 13(Suppl. 2):1-13. PMID 18578063.
4. Bertagnolio S., Parkin N.T., Jordan M., Brooks J., Garcia-Lerma J.G. Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev. 2010, 12:195-208. PMID 21179184.
5. Edelstein R.E., Nickerson D.A., Tobe V.O., Manns-Arcuino L.A., Frenkel L.M. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J. Clin. Microbiol. 1998, 36:569-572. PMID 9466779. PMC104580.
6. Ellis G.M., Mahalanabis M., Beck I.A., Pepper G., Wright A., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Frenkel L.M. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J. Clin. Microbiol. 2004, 42:3670-3674. pii:42/8/3670. PMC497615. 10.1128/JCM.42.8.3670-3674.2004.
7. Eshleman S.H., Hoover D.R., Chen S., Hudelson S.E., Guay L.A., Mwatha A., Fiscus S.A., Mmiro F., Musoke P., Jackson J.B., Kumwenda N., Taha T. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J. Infect. Dis. 2005, 192:30-36. pii:JID34089. 10.1086/430764.
8. Eshleman S.H., Hoover D.R., Chen S., Hudelson S.E., Guay L.A., Mwatha A., Fiscus S.A., Mmiro F., Musoke P., Jackson J.B., Kumwenda N., Taha T. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005, 19:2167-2169. 10.1097/00002030-200512020-00015.
9. Halvas E.K., Wiegand A., Boltz V.F., Kearney M., Nissley D., Wantman M., Hammer S.M., Palmer S., Vaida F., Coffin J.M., Mellors J.W. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment - experienced patients. J. Infect. Dis. 2010, 201:672-680. PMC2835354. 10.1086/650542.
10. Jallow S., Kaye S., Schutten M., Brandin E., Albert J., McConkey S.J., Corrah T., Whittle H., Vanham G., Rowland-Jones S., Janssens W. Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J. Clin. Microbiol. 2007, 45:1565-1571. pii:JCM.02220-06. PMC1865891. 10.1128/JCM.02220-06.
11. Johnson J.A., Li J.F., Morris L., Martinson N., Gray G., McIntyre J., Heneine W. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 2005, 192:16-23. pii:JID34101. 10.1086/430741.
12. Kuonza L.R., Tshuma C.D., Shambira G.N., Tshimanga M. Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study. BMC Public Health 2010, 10:218. pii:1471-2458-10-218. PMC2873585. 10.1186/1471-2458-10-218.
13. Martinson N.A., Morris L., Gray G., Moodley D., Pillay V., Cohen S., Dhlamini P., Puren A., Bhayroo S., Steyn J., McIntyre J.A. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J. Acquir. Immune Defic. Syndr. 2007, 44:148-153. 10.1097/QAI.0b013e31802b920e.
14. Micek M.A., Blanco A.J., Beck I.A., Dross S., Matunha L., Montoya P., Seidel K., Gantt S., Matediane E., Jamisse L., Gloyd S., Frenkel L.M. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin. Infect. Dis. 2010, 50:1405-1414. PMC3038662. 10.1086/652151.
15. Wallis C.L., Mahomed I., Morris L., Chidarikire T., Stevens G., Rekhviashvili N., Stevens W. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J. Virol. Methods 2005, 125:99-109. pii:S0166-0934(05)00017-0. 10.1016/j.jviromet.2005.01.004.
16. Zimbabwe, United Nations General Assembly Special Session, Report on HIV and AIDS, January 2008 to December 2009. http://data.unaids.org/pub/Report/2010/zimbabwe_2010_country_progress_report_en.pdf.
17. Zimbabwe, Prevention of Mother-to-Child Transmission (PMTCT) Report 2010. http://www.unicef.org/aids/files/Zimbabwe_PMTCTFactsheet_2010.pdf.